Key Takeaways
- Growth downgrade on biotech funding: Revenue growth guidance was cut from mid-teens to around double digits in constant currency, as reduced US biotech funding hit Discovery Services.
- Margin compressed 226 bps YoY: EBITDA from operations margin fell to 27%, driven by higher material costs and other expenses, partially offset by lower forex loss.
- Stelis facility acquired at a discount: The biologics manufacturing facility was concluded at a revised gross value of ₹617 crores, down from ₹702 crores, adding 20,000 litres of capacity.
- Early signs of funding stabilization: Management noted early signs that US biotech funding levels are stabilizing, though the near-term outlook remains for sustained but slower growth.
- What to watch next quarter: Whether the Stelis facility repurposing stays on track for 2H FY25, any further revision to the full-year growth outlook, and confirmation that the biotech funding trough is behind.
Revenue Performance & Segment Mix
- 9% YoY growth, Discovery Services soft: Overall revenue grew 9% YoY in Q3, with Dedicated Centers and Development and Manufacturing Divisions performing well while Discovery Services was impacted by the slowdown in US biotech funding.
- Manufacturing Services progressing: Continued good progress was reported on the long-term biologics manufacturing partnership with Zoetis.
- 9M revenue up 17%: Revenue from operations for the first nine months rose 17% to 2,571.7 crore, with PAT before exceptional items up 16% to 329.9 crore.
Stelis Biologics Facility Acquisition
- Deal closed at revised lower price: The acquisition of the multi-modal biologics manufacturing facility from Stelis Biopharma Ltd was concluded at a revised gross value of ₹617 crores, adjusted from the earlier ₹702 crores, reflecting retention of certain equipment not currently installed in the facility by the seller.
- Capacity added: The facility adds 20,000 litres of biologics drug substance manufacturing capacity and includes a commercial scale, high speed, fill-finish unit.
- Repurposing underway: The facility is being repurposed from vaccines to biologics manufacturing in preparation for revalidation, with operations expected in the second half of fiscal year 2025, subject to regulatory approvals.
- Capability expansion in Hyderabad: An assay biology capability was added at the Hyderabad campus to complement existing DMPK and Compound Management facilities.
Hunt: "we concluded the acquisition of the multi-modal biologics manufacturing facility from Stelis Biopharma Ltd and we have embarked on repurposing the facility from vaccines to biologics manufacturing in preparation for revalidation. We expect the facility to be ready for operations in the second half of fiscal year 2025, subject to regulatory approvals."
Margin & Cost Structure
- EBITDA margin fell 226 bps YoY to 27%: The decline was driven by higher material costs, up 159 bps as a percentage of revenue, and higher other expenses, up 131 bps, partially offset by lower foreign exchange loss.
- Staff costs flat as a share of revenue: Staff costs remained at 28% of revenue YoY, with a 10% absolute increase.
- Below-the-line items mixed: Other income rose 70% YoY to 29.3 crore, depreciation and amortisation increased 14% YoY to 108.1 crore, finance costs decreased 21% YoY to 10.8 crore, and tax expense decreased 9% YoY to 27.4 crore.
- 9M margin also under pressure: EBITDA from operations margin for the first nine months declined 108 bps to 27%.
Demand Environment & Biotech Funding
- US biotech funding squeeze is the root cause: Reduced funding in the US biotech segment directly impacted demand in Discovery Services, the segment most exposed to early-stage R&D spending by smaller biotech clients.
- Early stabilization signals emerging: Management noted it is starting to see early signs of funding levels stabilizing, though the near-term outlook remains for sustained but slower growth.
- Medium-to-long term thesis intact: Industry fundamentals for pharma outsourcing remain positive for the medium-to-long term, suggesting the current softness is viewed as cyclical rather than structural.
Balance Sheet & Investment Funding
- Investments funded by internal accruals: With strong operating cash flows, the company expects investments, including the Stelis facility repurposing, to be funded by internal accruals.
Biswas: "With strong operating cash flows, we expect these investments to be funded by internal accruals."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue growth | Around double digits in constant currency (downgraded from mid-teens) | FY24 |
| Stelis facility operational | Ready for operations, subject to regulatory approvals | Second half of FY25 |
| Investment funding | Funded by internal accruals with strong operating cash flows | Ongoing |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue from operations | ₹854 crores, up 9% YoY |
| Reported revenue | ₹883 crores, up 10% YoY |
| Reported EBITDA | ₹261 crores, up 5% YoY |
| EBITDA margin | 30%, vs 31% in Q3 FY23 |
| EBITDA from operations margin | 27%, vs 29% in Q3 FY23, -226bps |
| EBIT from operations margin | 14%, vs 17% in Q3 FY23, -288bps |
| PAT before exceptional items | ₹115 crores, up 4% YoY |
| PAT margin | 13%, vs 14% in Q3 FY23 |
| PAT after exceptional items | ₹112 crores, up 2% YoY |
| Revenue from operations 9M FY24 | ₹2,572 crores, up 17% YoY |
| PAT before exceptional items 9M FY24 | ₹330 crores, up 16% YoY |
| Full-year revenue growth guidance | around double digits in constant currency, revised from mid-teens constant currency growth |
| Stelis acquisition revised gross value | ₹617 crores, adjusted from earlier gross value of ₹702 crores |
| Stelis facility biologics drug substance capacity addition | 20,000 litres, expected operational in second half of FY25 subject to regulatory approvals |
| Exceptional item (net of tax) | 3 crore, transaction costs relating to acquisition of Stelis Biopharma facility |